Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta

After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.